Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

TD Cowen analysts said in a note to investors that the third quarter was the third time in five years that Exact Sciences, ...

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor ...

Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment ...

QRG Capital Management Inc. grew its stake in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 13.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The ...

Guardant Health stock jumped Thursday on an "impressive" third-quarter report following the launch of its cancer detection test, Shield.

Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.

Why is the expansion of our universe accelerating? Twenty-five years after its discovery, this phenomenon remains one of the greatest scientific mysteries. Solving it involves testing the fundamental ...

Madison-based Exact Sciences Corp. on Tuesday reported third-quarter results worse than analysts expected. The biomedical giant best known for its Cologuard at-home colon cancer screening test ...